Soleno Stock Delisted From Nasdaq After $2.9 Billion Neurocrine Deal
Soleno Therapeutics’ time on Nasdaq wrapped last week after Neurocrine Biosciences finished its $2.9 billion all-cash buyout. SLNO shareholders got a set $53 per share instead of trading price. Nasdaq said May 15 was the last day for Soleno stock, with suspension in place starting May 19. No catch-up this weekend, with U.S. equity markets closed Saturday and Nasdaq’s holiday calendar confirming markets will also be shut Monday, May 25, for Memorial Day. Trading is set to resume Tuesday.